Managing heart disease diabetes and the heart: Compromised myocardial function - A common challenge

European Heart Journal, Supplement

Volumn 5, Issue B, 2003, Pages

  Bartnik, M ^a   Malmberg, K ^a   Ryden L ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Diabetes mellitus; Heart failure; Myocardial metabolism; Prognosis; Treatment

Indexed keywords

ALTEPLASE; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARNITINE PALMITOYLTRANSFERASE; CARVEDILOL; DICHLOROACETIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; INSULIN; LISINOPRIL; LOOP DIURETIC AGENT; METOPROLOL; STREPTOKINASE; TRIMETAZIDINE;

ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE HEART FAILURE; DIABETES CONTROL; DIABETES MELLITUS; DIURETIC THERAPY; DRUG MECHANISM; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE METABOLISM; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; INSULIN TREATMENT; PRIORITY JOURNAL; PROGNOSIS;

EID: 0037234064     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1520-765X(03)90039-3     Document Type: Article

References (79)

1. King H, Aubert RE, Herman WH. Global burden of diabetes 1995-2025. Prevalence, numerical estimates and projections. Diabetes Care 1998; 21: 1414-31.
2. Kanters SD, Banga JD, Stolk RP, Algra A. Incidence and determinants of mortality and cardiovascular events in diabetes mellitus: a metaanalysis. Vasc Med 1999, 4: 67-75.
3. Laakso M, Lehto S. Epidemiology of macrovascular disease in diabetes. Diabetes Rev 1997; 5: 294-315.
4. EUROASPIRE II Group. Lifestyle & risk factors management and use of drug therapies in coronary patients from 15 countries. Eur Heart J 2001; 22: 554-72.
5. Norhammar A, Tenerz A, Nilsson G, et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002; 359: 2140-4.
6. Reis SE, Holubkov R, Edmundowicz D, et al. Treatment of patients admitted to the hospital with congestive heart failure: speciality-related disparities in practice patterns and outcomes. J Am Coll Cardiol 1997; 30: 733-8.
7. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 1993; 22: 6A-13A.
8. Kannel WB, Ho K, Thom T. Changing epidemiological features of cardiac failure. Br Heart J 1994; 72(suppl): S3-9.
9. Cowie MR, Mosterd A, Wood D, et al. The epidemiology of heart failure. Eur Heart J 1997; 18: 208-25.
10. Remme WJ, Swedberg K for the ESC Task Force. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001; 22: 1527-60.
11. Zannad F, Briancon S, Juilliere Y, et al., and the EPICAL Investigators. Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: the EPICAL study. J Am Coll Cardiol 1999; 33: 734-42.
12. Kitzman DW, Gardin JM, Gottdiener JS, et al., Cardiovascular Health Study Research Group. Importance of heart failure with preserved systolic function in patients =65 years of age. CHS Research Group. Cardiovascular Health Study. J Am Coll Cardiol 2001; 87:413-9.
13. Kannel WB. Need and prospects for prevention of cardiac failure. Eur J Clin Pharmacol 1996; 49(suppl 1): S3-9.
14. The NETWORK investigators. Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison. Eur Heart J 1998; 19: 481-9.
15. The CONSENSUS trial study group. Effect of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987; 316: 1429-35.
16. McKelvie RS,Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999; 100: 1056-64.
17. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979; 214: 2035-8.
18. Amato L, Paolisso G, Cacciatore F, et al., on behalf of the Observatorio Geriatrico Regione Campania Group. Congestive heart failure predicts the development of non-insulin dependent diabetes mellitus in the elderly. Diabetes Metab 1997; 23: 213-8.
19. Chae CU, Glynn RJ, Manson JE, Guralnik JM, Taylor JO, Pfeffer MA. Diabetes predicts congestive heart failure risk in the elderly. Circulation 1998; 98(suppl 1): 721.
20. Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 2000; 355: 773-8.
21. Suskin N, McKelvie RS, Rolueau J, Sigouin C, Wieeek E, Yusuf S. Increased insulin and glucose levels in heart failure. J Am Coll Cardiol 1998; 31(suppl A): 249A.
22. Ämlöv J, Lind L, Zethelius B, et al. Several factors associated with the insulin resistance syndrome are predictors of left ventricular systolic dysfunction in a male population after 20 years of follow-up. Am Heart J 2001; 142: 720-4.
23. Swan JW, Walton C, Godsland IF, Clark AL, Coats AJ, Oliver MF. Insulin resistance in chronic heart failure. Eur Heart J 1994; 15: 1528-32.
24. Poole-Wilson PA. Chronic heart failure: cause, pathophysiology, prognosis, clinical manifestations, investigations. In: Julian DG, Camm AJ, Fox KF, Hall RJC, Poole-Wilson PA, eds. Diseases of the heart. London, Balliere-Tindall, 1989: 24-36.
25. Cohen-Solal A. Diastolic heart failure: myth or reality? Eur J Heart Fail 2002; 4: 395-400.
26. Yu C-M, Lin H, Yang H, King S-L, Zhang Q, Lee SW-L. Progression of systolic abnormalities in patients with 'isolated' diastolic heart failure and diastolic dysfunction. Circulation 2002; 105: 1195-201.
27. Cleland J. IMPROVEMENT of heart failure. Presented at the Annual Meeting of the European Society of Cardiology, Amsterdam, 2000.
28. Euro Heart Failure. Report at the Annual Congress of the European Society of Cardiology, Stockholm, 2001.
29. Adams KF, Sueta CA, Gheorghiade M, et al., for the FIRST Investigators. Gender differences in survival in advanced heart failure. Insights from the FIRST Study. Circulation 1999; 99: 1816-21.
30. Kalon KL, Andersson KM, Kannel WB, Grossman W, Levy D. Survival after onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993; 88: 107-15.
31. Jong P, Vowinckel E, Liu PP, Gong Y, Tu JV. Prognosis and determinants of survival in patients newly hospitalized for heart failure: a population-based study. Arch Intern Med 2002; 162: 1689-94.
32. Vasan RS, Iarson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction. J Am Coll Cardiol 1999; 33: 1948-55.
33. Mosterd A, Cost B, Hoes AW, et al. The prognosis of heart failure in the general population. The Rotterdam Study. Eur Heart J 2001; 22: 1318-27.
34. Stone P, Muller J, Hartwell T, et al., for the MILIS Study group. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to adverse prognosis. J Am Coll Cardiol 1989; 54: 49-57.
35. Melchior T, Gadsboll P, Hildebrandt P, Kober L, Torp-Pedersen C. Clinical characteristics, left and right ventricular ejection fraction, and long term prognosis in patients with non-insulin dependent diabetes surviving an acute myocardial infarction. Diabet Med 1996; 13: 450-6.
36. McGuire DK, Emanuelsson H, Granger CB, et al., for the GUSTO-IIb investigators. Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Eur Heart J 2000; 21: 1750-8.
37. Malmberg K, Rydén L, Efendic S. A randomized study of insulinglucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction: effects on 1-year mortality. J Am Coll Cardiol 1995; 26: 57-65.
38. Bell DSH: Diabetic cardiomyopathy. A unique entity or a complication of coronary artery disease? Diabetes Care 1995; 18: 708-14.
39. Dubrey SW, Raeveley DR, Seed M, et al. Risk factors for cardiovascular disease in IDDM. A study of identical twins. Diabetes 1994;43:831-5.
40. Zoneraich S, Mollura JL. Diabetes and the heart: state of the art in the 1990s. Can J Cardiol 1993; 9: 293-9.
41. Hardin N. The myocardial and vascular pathology of diabetic cardiomyopathy. Coron Artery Dis 1996: 7: 99-108.
42. Shehadeh A, Regan TJ. Cardiac consequences of diabetes mellitus. Clin Cardiol 1995; 18: 301-5.
43. UKPDS-35. Association of glycaemia with macrovascular and microvascular complication of type 2 diabetes: a prospective observational study. BMJ 2000; 321: 405-12.
44. Suskin N, McKelvie RS, Bums RJ, et al. Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure, Eur Heart J 2000; 21: 1368-75.
45. Iribarren C, Karter AJ, Go AS, et al. Glycemic control and heart failure among adult patients with diabetes. Circulation 2001; 103: 2668-73.
46. Personage W, Hetmanski D, Cowley A. Differentiation of the metabolic and vascular effects of insulin in insulin resistance in patients with chronic heart failure. Am J Cardiol 2002; 89: 696-703.
47. Holzmann M, Olsson A, Johansson J, Jensen-Urstad M. Left ventricular diastolic function is related to glucose in a middle-aged population. J Intern Med 2002; 251: 415-20.
48. Braunwald E, Bristow R. Congestive heart failure: fifty years of progress. Circulation 2000; 102(suppl 4): 14-23.
49. Stanley WC. Metabolic dysfunction in the diabetic heart. In: Stanley WC, Rydén L, eds. The diabetic coronary patient. London, Science Press Ltd, 1999: 13-28.
50. Taegtmeyer H, McNulty P, Young M. Adaptation and mal-adaptation of the heart in diabetes. Part I. Circulation 2002; 105: 1727-33.
51. King LM, Opie LH. Glucose delivery is a major determinant of glucose utilisation in the ischemic myocardium with a residual coronary flow. Cardiovasc Res 1998; 39: 381-92.
52. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose-fatty acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963; 13: 785-9.
53. Young M, McNulty P, Taegtmeyer H. Adaptation and mal-adaptation of the heart in diabetes. Part II. Circulation 2002; 105: 1861-70.
54. Windt L, Cox K, Hofstra L, Doevendans P. Molecular and genetic aspects of cardiac fatty acid homeostasis in health and disease. Eur Heart J 2001; 23: 774-87.
55. Way KJ, Katai N, King GL. Protein kinase C and the development of diabetic vascular complications. Diabet Med 2001; 18: 945-59.
56. +-adenosine triphosphatase by hyperglycaemia involving activation of protein kinase C and cytosolic phospholipase A2. J Clin Invest 1995; 96: 733-40.
57. Alpert N, Mulieri L, Warshaw D. The failing human heart. Cardiovasc Res 2002; 54: 1-10.
58. Rodrigues B, Cam MC, McNeill JH. Myocardial substrate metabolism: implications for diabetic cardiomyopathy. J Mol Cell Cardiol 1995; 27: 169-79.
59. Guzik TJ, Mussa S, Gastaldi D, et al. Mechanisms of incereased vascular superoxide production in human diabetes mellitus. Role of NADP(H) oxidase and endothelial nitric oxide synthase. Circulation 2002; 105: 1656-62.
60. The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991; 325: 293-302.
61. The SOLVD investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685-91.
62. Rydén L, Armstrong PW, Cleland JGF, et al., on behalf of the ATLAS Study Group. Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Eur Heart J 2000; 21: 1967-78.
63. Herings RMC, deBoer A, Stricker BHC, Leufkens HGM, Porsius A. Hypoglycemia associated with the use of inhibitors of angiotensin-converting enzyme. Lancet 1996; 345: 1195-8.
64. Morris AD, Boyle DIR, McMahon AD, et al. ACE inhibitor use is associated with hospitalisation for severe hypoglycemia in patients with diabetes. Diabetes Care 1997; 20: 1363-79.
65. Malmberg K, Herlitz J, Hjalmarsson A, Rydén L. Effects on metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infarction. Retrospective data from two large scale studies. Eur Heart J 1989; 10: 423-8.
66. Bristow M, Gilbert EM, Abraham WT, et al. Effect of carvedilol on LV function and mortality in diabetic versus non-diabetic patients with ischemic or nonischemic dilated cardiomyopathy. Circulation 1996; 84(suppl): 664.
67. Eichhom EJ, Hesch CN, Barnett JH, et al. Effect on metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 1994; 24: 1310-20.
68. Wallhaus TR, Taylor M, DeGrado TR, et al. Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. Circulation 2001; 103: 2441-6.
69. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000; 283: 1295-302.
70. Bersin RM, Wolfe C, Kwasman M, et al. Improved hemodynamic function and mechanical efficiency in congestive heart failure with sodium dichloroactetate. J Am Coll Cardiol 1994; 23: 1617-24.
71. Schmidt-Schweda St, Holubarsch Ch. First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin Sci 2000; 99: 27-35.
72. Szwed H, Sadowski Z, Pachocki R, et al. The anti-ischemic effects and tolerability of trimetazidine in coronary diabetic patients. A substudy from TRIMPOL-1. Cardiovasc Drugs Ther 1999; 13: 217-22.
73. Monti LD, Setola E, Palloshi A, et al. Metabolic and endothelial effects of trimetazidine in type 2 diabetic patients with ischemic dilated cardiomyopathy [abstract 260]. Diabetologia 2001; 44: 68.
74. Blardi P, de Lalla A, Volpi L, Auteri A, Di Perri T. Increase of adenosine plasma levels after oral trimetazidine: a pharmacological preconditioning? Pharmacol Res 2002; 45: 69-72.
75. McMurray J, Pfeffer MA. New therapeutic options in congestive heart failure: part 1. Circulation 2002; 105: 2099-106.
76. Malmberg K, Norhammar A, Wedel H, Rydén L. Glucometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long term results from the DIGAMI study. Circulation 1999; 99: 2626-32.
77. Von Bibra H, Hansen A, Dounis V, Bystedt, Malmberg K, Rydén L. Diastolic myocardial function and myocardial microvasculature reserve improve with intense insulin treatment in type 2 diabetic patients [abstract 265]. Diabetologia 2001; 44: 68.
78. Joslin EP. The treatment of diabetes mellitus, 3rd edition. London, H. Kimpton, 1924.
79. Almbrand B, Johannesson B, Sjöstrand B, Malmberg K, Rydén L. Cost-effectiveness of intense insulin treatment after acute myocardial infarction in patients with diabetes mellitus; results from the DIGAMI study. Eur Heart J 2000; 21: 733-9.